◆英語タイトル:AC Immune SA (ACIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9764
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer’s disease. AC Immune is headquartered in Lausanne, Switzerland.
AC Immune SA (ACIU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AC Immune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9
AC Immune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AC Immune SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
AC Immune Raises US$22 Million In Series D Financing Round 11
Partnerships 12
AC Immune Enters into Agreement with Essex Bio-Technology 12
AC Immune Enters into Partnership with Biogen 13
AC Immune Enters into Research Agreement with Janssen Pharma 14
AC Immune Enters Into Co-Development Agreement With University of Basel 15
Licensing Agreements 16
AC Immune Enters into Licensing Agreement with Janssen Pharma 16
AC Immune Enters Into License Agreement With Piramal Imaging 17
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 19
Equity Offering 21
AC Immune Raises USD17.6 Million in Rights Offering of Shares 21
AC Immune Raises USD100 Million in Rights Offering of Shares 23
AC Immune Prices IPO for USD66 Million 25
AC Immune Raises USD43.5 Million in Private Placement of Series E Preferred Shares 27
AC Immune SA – Key Competitors 28
AC Immune SA – Key Employees 29
AC Immune SA – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Financial Announcements 31
Aug 08, 2018: Ac Immune reports second quarter 2018 financial results and corporate update 31
May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update 33
Mar 20, 2018: AC Immune reports full-year 2017 financial results – successful first year as a public company 35
Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update 38
Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results 40
May 11, 2017: AC Immune Reports First Quarter 2017 Financial Results 42
Mar 17, 2017: AC Immune Reports Full Year 2016 Financial Results and R&D Update 44
Government and Public Interest 46
Oct 03, 2017: AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinsons Research 46
Product News 47
11/21/2017: AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimers and other Neurodegenerative Diseases 47
11/01/2018: AC Immune to Present at 2018 Society for Neurosciences Meeting 48
Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
AC Immune SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AC Immune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AC Immune SA, Deals By Therapy Area, 2012 to YTD 2018 8
AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9
AC Immune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AC Immune Raises US$22 Million In Series D Financing Round 11
AC Immune Enters into Agreement with Essex Bio-Technology 12
AC Immune Enters into Partnership with Biogen 13
AC Immune Enters into Research Agreement with Janssen Pharma 14
AC Immune Enters Into Co-Development Agreement With University of Basel 15
AC Immune Enters into Licensing Agreement with Janssen Pharma 16
AC Immune Enters Into License Agreement With Piramal Imaging 17
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 19
AC Immune Raises USD17.6 Million in Rights Offering of Shares 21
AC Immune Raises USD100 Million in Rights Offering of Shares 23
AC Immune Prices IPO for USD66 Million 25
AC Immune Raises USD43.5 Million in Private Placement of Series E Preferred Shares 27
AC Immune SA, Key Competitors 28
AC Immune SA, Key Employees 29
List of Figures
AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AC Immune SA, Medical Devices Deals, 2012 to YTD 2018 9